Patents Assigned to ML Technology Venture
  • Patent number: 5305083
    Abstract: A random access monochromator is disclosed. This device has no mechanical parts and eliminates the need to scan sequentially the wavelengths of light contained in a light spectrum to select a desired wavelength or wavelengths from the spectrum. The device has high speed switching means, permits one to select multiple wavelengths and bandwidths at the same time, and has the ability to correct for non-linearity in prisms caused by their nonlinear or second order dispersion of light.
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: April 19, 1994
    Assignee: ML Technology Ventures, L.P.
    Inventors: Charles G. J. Marianik, Carlos Zarate, Gilbert M. Levy
  • Patent number: 5240706
    Abstract: A method for protecting an animal, in particular swine, against mycoplasma pneumonia by administering intranasally to the animal a vaccine containing one or more proteins which elicits an antibody which recognizes a Mycoplasma hyopneumoniae antigen which lacks immunosuppressive activity. A particularly preferred intranasal vaccine includes the 74.5 kDa antigen of Mycoplasma hyopneumoniae. The 74.5 kDa antigen may be of recombinant origin.
    Type: Grant
    Filed: April 7, 1989
    Date of Patent: August 31, 1993
    Assignee: ML Technology Ventures, L.P.
    Inventor: Daryl Faulds
  • Patent number: 5176910
    Abstract: A vaccine for protection against swine dysentery which comprises T. hyodysenteriae hemolysin and a physiologically acceptable vehicle for said peptide. The vaccine contains the hemolysin in an amount effective for protecting against swine dysentery. The invention also relates to a method of protecting swine against swine dysentery by administering to swine the vaccine described above.
    Type: Grant
    Filed: January 17, 1989
    Date of Patent: January 5, 1993
    Assignee: ML Technology Ventures, L. P.
    Inventors: Michael McCaman, Raymond Slomiany
  • Patent number: 5030557
    Abstract: The binding of a nucleic acid probe with its complementary sequence in a targeted, single stranded nucleic acid is affected by the secondary and tertiary structure of the target nucleic acid. The rate and extent of hybridization of the probe with the targeted nucleic acid can be increased by the use of "helper" oligonucleotides. Helper oligonucleotides are selected to bind to the target nucleic acid and impose a different secondary and tertiary structure on the target to facilitate the binding of the probe to the target. The resulting hybrid of probe and target nucleic acid also exhibits a higher T.sub.m than the hybrid which results from addition of the probe alone.
    Type: Grant
    Filed: November 24, 1987
    Date of Patent: July 9, 1991
    Assignee: ML Technology Venture
    Inventors: James J. Hogan, Curt L. Milliman
  • Patent number: 4985243
    Abstract: A vaccine for protecting against a disease caused by a microorganism which does not synthesize nucleic acid precursors such as a Micoplasma organism, which contains nuclease and/or a nuclease fragment or derivative which produces antibodies which recognize nuclease secreted or available on the surface of the microorganism against which protection is to be afforded. A vaccine may also be prepared from an antibody or fragment or derivative thereof which recognizes such nuclease of such microorganism.
    Type: Grant
    Filed: January 20, 1988
    Date of Patent: January 15, 1991
    Assignee: ML Technology Ventures, L.P.
    Inventors: Daryl H. Faulds, Mimi Vishoot